[go: up one dir, main page]

AR048376A1 - C- glicosidos heterociclos fusionados sustituidos - Google Patents

C- glicosidos heterociclos fusionados sustituidos

Info

Publication number
AR048376A1
AR048376A1 ARP040102728A ARP040102728A AR048376A1 AR 048376 A1 AR048376 A1 AR 048376A1 AR P040102728 A ARP040102728 A AR P040102728A AR P040102728 A ARP040102728 A AR P040102728A AR 048376 A1 AR048376 A1 AR 048376A1
Authority
AR
Argentina
Prior art keywords
substituted
glycycles
glycycle
fusioned
absent
Prior art date
Application number
ARP040102728A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv, Tanabe Seiyaku Co filed Critical Janssen Pharmaceutica Nv
Publication of AR048376A1 publication Critical patent/AR048376A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente se refiere a composiciones que contienen estos compuestos, y métodos para utilizarlos, por ejemplo para el tratamiento o rofilaxis de la diabetes y el Síndrome X. Reivindicacion 1: Un compuesto de la formula (1) en la cual: una de las líneas punteadas entre NR1 y X o entre X e Y está presente, o ambas están ausentes; dos de V. M y W son H y el tercero es como se muestra en la formula (2), R1 es H, alquilo C1-4, cuando la línea punteada entre NR1 y X está presente, R1 está ausente; X es N, C=O, CH; o C-Q-Z. Y es N-Q-Z o C-Q-Z, cuando X es N, C=O o CH; Y es CH, cuando X es C-Q-Z; Q=-(CH2)n-, donde n = 1 o 2; P = H, acilo C1-7 o (alcoxi C1-6)carbonilo; Z cestá sustituido o sin sustituir, y se selecciona de cicloalquilo C3-7, fenilo, heteroarilo de 5 o 6 miembros que presentan 1 o 2 heteroátomos independientemente seleccionados de N, O y S, un biarilo, biciclilo fusionado de 9 o 10 miembros y un heterobiciclilo fusionado, donde dicho heterobiciclilo fusionado presenta entre 1 y 4 heteroátomos independientemente seleccionados de N, O y S; o una sal aceptable desde el punto de vista farmacéutico del mismo.
ARP040102728A 2003-08-01 2004-07-30 C- glicosidos heterociclos fusionados sustituidos AR048376A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49152303P 2003-08-01 2003-08-01
US49153403P 2003-08-01 2003-08-01
US51921003P 2003-11-12 2003-11-12
US57973004P 2004-06-15 2004-06-15

Publications (1)

Publication Number Publication Date
AR048376A1 true AR048376A1 (es) 2006-04-26

Family

ID=34120044

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102728A AR048376A1 (es) 2003-08-01 2004-07-30 C- glicosidos heterociclos fusionados sustituidos

Country Status (9)

Country Link
US (4) US7094763B2 (es)
EP (1) EP1679965A4 (es)
AR (1) AR048376A1 (es)
AU (1) AU2004261660A1 (es)
CA (1) CA2549015A1 (es)
EA (1) EA009768B1 (es)
IL (1) IL175489A0 (es)
TW (1) TW200521131A (es)
WO (1) WO2005012318A2 (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101001848B1 (ko) * 2003-03-14 2010-12-17 고토부키 세이야쿠 가부시키가이샤 Ｃ-글리코시드 유도체 또는 이의 염, 및 이를 포함하는 의약 조성물
CN103214471B (zh) * 2003-08-01 2018-02-06 田边三菱制药株式会社 具有钠依赖型葡萄糖转运体抑制活性的化合物的制备方法
WO2005012318A2 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica Nv Substituted fused heterocyclic c-glycosides
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
WO2005085237A1 (ja) * 2004-03-04 2005-09-15 Kissei Pharmaceutical Co., Ltd. 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
IL218714A (en) 2004-03-16 2013-02-28 Boehringer Ingelheim Int Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
CA2574451A1 (en) * 2004-07-27 2006-02-02 Boehringer Ingelheim International Gmbh D-glucopyranosyl phenyl-substituted cyclene, medicaments containing these compounds, their use, and method for the production thereof
MX2007003785A (es) * 2004-09-29 2007-07-12 Kissei Pharmaceutical Compuesto heterociclico nitrogenoso 1-(b-d-glicopiranosil)-3, composicion medicinal que contiene el mismo, y uso medicinal del mismo.
JP5086643B2 (ja) * 2004-11-18 2012-11-28 キッセイ薬品工業株式会社 １−置換−３−（β−Ｄ−グリコピラノシル）含窒素ヘテロ環化合物、及びそれを含有する医薬
TW200635599A (en) 2004-12-16 2006-10-16 Boehringer Ingelheim Int Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
TWI365186B (en) 2005-01-31 2012-06-01 Mitsubishi Tanabe Pharma Corp Indole derivatives
AR053329A1 (es) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
DE602006009772D1 (de) 2005-02-23 2009-11-26 Boehringer Ingelheim Int Glucopyranosylsubstituierte ((hetero)arylethynyl-benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose-cotransporters typ 2 (sglt2)
WO2006099245A1 (en) * 2005-03-11 2006-09-21 Elixir Pharmaceuticals, Inc. Sirt inhibitors that bind to nad
CA2605245A1 (en) 2005-04-15 2006-10-19 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
CN101198326B (zh) * 2005-04-20 2011-10-12 橘生药品工业株式会社 Ⅱ型糖尿病治疗用的组合药物制剂
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
TW200726755A (en) * 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
EP1910390B1 (en) 2005-07-27 2010-05-19 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted ((hetero)cycloalyklethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter (sglt) inhibitors
ATE484499T1 (de) 2005-08-30 2010-10-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
AU2006289093A1 (en) 2005-09-08 2007-03-15 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
BRPI0707849A2 (pt) 2006-02-15 2011-05-10 Boehringer Ingelheim Int derivados de benzonitrila substituÍdos por glicopiranosila, composiÇÕes farmacÊuticas contendo tais compostos, seu uso e processo para sua fabricaÇço
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
JP5230613B2 (ja) * 2006-05-23 2013-07-10 テラコス・インコーポレイテッド グルコース輸送体阻害剤およびその使用方法
TWI432446B (zh) 2006-07-27 2014-04-01 Chugai Pharmaceutical Co Ltd 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
TWI418556B (zh) * 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
TWI403516B (zh) 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
CA2656847A1 (en) 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
AU2007307544A1 (en) 2006-10-13 2008-04-17 Chugai Seiyaku Kabushiki Kaisha Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes
WO2008049923A1 (en) 2006-10-27 2008-05-02 Boehringer Ingelheim International Gmbh CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
AU2007329490B2 (en) * 2006-12-04 2012-05-17 Janssen Pharmaceutica N.V. Thienyl-containing glycopyranosyl derivatives as antidiabetics
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
US8198464B2 (en) * 2006-12-21 2012-06-12 Astellas Pharma Inc. Method for producing C-glycoside derivative and intermediate for synthesis thereof
US7795228B2 (en) * 2006-12-28 2010-09-14 Theracos, Inc. Spiroheterocyclic glycosides and methods of use
WO2008109591A1 (en) 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
RU2492175C2 (ru) * 2007-04-02 2013-09-10 Теракос, Инк. Бензиловые производные гликозидов и способы их применения
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
NO2187742T3 (es) 2007-08-23 2018-03-24
SI2200606T1 (sl) 2007-09-10 2017-12-29 Janssen Pharmaceutica N.V. Postopek za pripravo spojin, uporabnih kot inhibitorjev SGLT
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
FR2926021B1 (fr) * 2008-01-03 2012-12-14 Oreal Utilisation de derives c-glycoside a titre d'actif vasculaire
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
HUE029970T2 (en) * 2008-08-22 2017-04-28 Theracos Sub Llc Processes for the preparation of sglt2 inhibitors
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
WO2010075500A1 (en) 2008-12-23 2010-07-01 Stemcells California, Inc Target populations of oligodendrocyte precursor cells and methods of making and using same
JP5685550B2 (ja) 2009-02-13 2015-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
MX344264B (es) 2009-02-13 2016-12-09 Boehringer Ingelheim Int Gmbh * Inhibidor de sglt-2 para el tratamiento de diabetes mellitus tipo 1, diabetes mellitus tipo 2, tolerancia deteriorada a la glucosa o hiperglucemia.
WO2010128152A1 (en) * 2009-05-07 2010-11-11 Novartis Ag Fused heterocyclic c-glycosides for the treatment of diabetes
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
ES2416459T3 (es) 2009-07-10 2013-08-01 Janssen Pharmaceutica, N.V. Procedimiento de cristalización para 1-( -D-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno
AU2010276369B2 (en) * 2009-07-22 2013-07-04 Med-El Elektromedizinische Geraete Gmbh Magnetic attachment arrangement for implantable device
CN101991580B (zh) * 2009-08-28 2013-03-20 杏辉天力（杭州）药业有限公司 以羊毛甾烷及茯苓萃取物治疗糖尿病的用途
HUE026133T2 (en) 2009-09-30 2016-05-30 Boehringer Ingelheim Int Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
AU2010303123B2 (en) 2009-09-30 2014-02-27 Boehringer Ingelheim International Gmbh Method for the preparation of a crystalline form of 1-chloro-4- (Beta-D-glucopyranos-1-yl)-2-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)benzene
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
ME02634B (me) * 2009-10-14 2017-06-20 Janssen Pharmaceutica Nv Proces za pripremu jedinjenja koja su korisna kao inhibitori sglt2
JP5696156B2 (ja) 2009-11-02 2015-04-08 ファイザー・インク ジオキサ−ビシクロ［３．２．１］オクタン−２，３，４−トリオール誘導体
ES2596291T3 (es) 2010-05-11 2017-01-05 Janssen Pharmaceutica, N.V. Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
KR101913587B1 (ko) 2011-04-13 2018-10-31 얀센 파마슈티카 엔.브이. Sglt2의 억제제로서 유용한 화합물의 제조 방법
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
HK1215398A1 (zh) 2013-04-05 2016-08-26 勃林格殷格翰国际有限公司 依帕列净的治疗用途
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PT2986304T (pt) 2013-04-18 2022-02-25 Boehringer Ingelheim Int Composição farmacêutica, métodos para o tratamento e suas utilizações
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
MX2017012893A (es) * 2015-04-07 2018-01-15 Intercept Pharmaceuticals Inc Composiciones farmaceuticas para terapias combinadas.
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
KR101987403B1 (ko) 2016-01-04 2019-06-10 제일약품주식회사 융합 페닐 환이 포함된 c-글루코시드 유도체 또는 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
WO2017141202A1 (en) 2016-02-17 2017-08-24 Lupin Limited Complex of sglt2 inhibitor and process for preparation thereof
MA46742A (fr) 2016-11-10 2019-09-18 Boehringer Ingelheim Int Composition pharmaceutique, méthodes de traitement et leurs utilisations
CN110041378B (zh) * 2019-05-25 2021-04-09 扬州工业职业技术学院 一种苯并噁唑酮糖苷及其制备工艺与应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584369A (en) * 1981-07-31 1986-04-22 Sloan-Kettering Institute For Cancer Research Anti-leukemic beta-glycosyl C-nucleosides
US5334225A (en) 1992-07-15 1994-08-02 Kao Corporation Keratinous fiber dye composition containing a 2-substituted amino-5-alkylphenol derivative coupler
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
US5731292A (en) * 1992-11-12 1998-03-24 Tanabe Seiyaku Co., Ltd. Dihydrochalcone derivatives which are hypoglycemic agents
US6297363B1 (en) 1993-02-12 2001-10-02 Nomura Co., Ltd. Glycoside indoles
US5830873A (en) 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
JP3059088B2 (ja) * 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
ES2176600T3 (es) * 1996-12-26 2002-12-01 Tanabe Seiyaku Co Derivado de la propiofenona y procedimientos para su preparacion.
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
CN1384825A (zh) 1999-08-31 2002-12-11 马克西亚药品公司 亚苄基－噻唑烷二酮及其类似物以及它们在治疗糖尿病中的应用
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6627611B2 (en) * 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
WO2001064669A1 (en) 2000-03-03 2001-09-07 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents
EP1270584B1 (en) 2000-03-17 2005-12-07 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
JP2004536047A (ja) 2001-04-11 2004-12-02 ブリストル−マイヤーズ　スクイブ　カンパニー 糖尿病処置用ｃ−アリールグルコシドのアミノ酸複合体および方法
CA2448741C (en) 2001-05-30 2010-06-22 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
JP4399254B2 (ja) 2001-06-20 2010-01-13 キッセイ薬品工業株式会社 含窒素複素環誘導体、それを含有する医薬組成物、その医薬用途およびその製造中間体
WO2003011880A1 (fr) 2001-07-31 2003-02-13 Kissei Pharmaceutical Co., Ltd. Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
US20030087843A1 (en) 2001-09-05 2003-05-08 Washburn William N. O-pyrazole glucoside SGLT2 inhibitors and method of use
US6617313B1 (en) 2002-03-13 2003-09-09 Council Of Scientific And Industrial Research Glucopyranoside and process of isolation thereof from pterocarpus marsupium pharmaceutical composition containing the same and use thereof
US6562791B1 (en) * 2002-03-29 2003-05-13 Council Of Scientific And Industrial Research Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
WO2003087093A1 (en) 2002-04-08 2003-10-23 Council Of Scientific And Industrial Research Novel glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
KR101001848B1 (ko) 2003-03-14 2010-12-17 고토부키 세이야쿠 가부시키가이샤 Ｃ-글리코시드 유도체 또는 이의 염, 및 이를 포함하는 의약 조성물
JP2004300102A (ja) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
WO2005012318A2 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica Nv Substituted fused heterocyclic c-glycosides

Also Published As

Publication number Publication date
US7094763B2 (en) 2006-08-22
WO2005012318A3 (en) 2005-12-15
AU2004261660A1 (en) 2005-02-10
US7482330B2 (en) 2009-01-27
IL175489A0 (en) 2009-02-11
CA2549015A1 (en) 2005-02-10
EP1679965A4 (en) 2009-05-27
EA009768B1 (ru) 2008-04-28
EP1679965A2 (en) 2006-07-19
US20090105162A1 (en) 2009-04-23
US7816328B2 (en) 2010-10-19
EA200601552A1 (ru) 2007-02-27
WO2005012318A2 (en) 2005-02-10
TW200521131A (en) 2005-07-01
US20100004160A1 (en) 2010-01-07
US20050037980A1 (en) 2005-02-17
US20060229260A1 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
AR048376A1 (es) C- glicosidos heterociclos fusionados sustituidos
AR048282A1 (es) Indol- o - glucosidos sustituidos
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR048375A1 (es) Indazol-o-glucosidos sustituidos
BRPI0412659A (pt) isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto
AR048377A1 (es) Benzoimidazol-, benzotriazol- y benzoimidazolona - o- glucosidos sustituidos
CO5570660A2 (es) Indazolilpirrolotriazinas c-6 modificadas
ATE358479T1 (de) 1-(2,3-dimethyl-phenyl)-ethyl-1,3-dihydro- imidazol-2-thion als nicht-sedierender alpha 2a agonist
AR055150A1 (es) Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso
AR053774A1 (es) Derivados de sulfonilbencimidazol. composiciones farmaceuticas.
EA201791254A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
PE20030976A1 (es) Piridinoilpiperidinas como agonistas de 5-ht1f
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
EA200200912A1 (ru) Новые производные индолин-2-она, их получение и их применение в качестве лигандов рецепторов окситоцина
EA200970124A1 (ru) Производные 2-арилиндола в качестве ингибиторов npges-1
PE20040531A1 (es) Derivados de isoindolona, proceso de preparacion, compuestos intermedios de este proceso y composiciones farmaceuticas que los contienen
EA200500899A1 (ru) Антагонисты аденозиндифосфатного рецептора тромбоцитов
DE602004031410D1 (de) Inden derivate als pharmazeutika
CO5640109A2 (es) Compuestos triciclicos inhibidores de la farnesisl proteino transferasa y composiciones farmaceuticas que los contienen
PE20080283A1 (es) Profarmacos antimicrobianos de oxazolidinona
EA200300988A1 (ru) Производные фенил-гетероциклильных эфиров в качестве ингибиторов обратного захвата серотонина
BRPI0407386A (pt) Derivados de álcool de amino, composições farmacêuticas contendo os mesmos e uso destes
NO20071230L (no) Oksazolidinoner inneholdende oksindoler som antibakterielle midler

Legal Events

Date Code Title Description
FA Abandonment or withdrawal